GlassScriptPhysician profile
Daniel R Wynn
NPI 1710971700
$812,379.88
in general payments reported to CMS, 2019-2025
97 companies · $68K in 2025
The $68K reported for 2025 was more than what 97% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $218K · 2020: $73K · 2021: $112K · 2022: $170K · 2023: $74K · 2024: $96K · 2025: $68K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $145K · Consulting Fee: $45K · Food and Beverage: $25K · Travel and Lodging: $19K · Honoraria: $5,750 · Education: $287 · Gift: $40.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $144,669.50 |
| Consulting Fee | $44,746.75 |
| Food and Beverage | $24,501.83 |
| Travel and Lodging | $19,017.03 |
| Honoraria | $5,750.00 |
| Education | $287.16 |
| Gift | $40.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $225,769.37 | 2019-2025 | |
| Emd Serono, INC. | $198,867.21 | 2019-2025 | Mavenclad, Mavenclad |
| E.R. Squibb & Sons, L.L.C. | $92,329.72 | 2020-2025 | Zeposia |
| Horizon Therapeutics Plc | $27,549.15 | 2021-2023 | Uplizna |
| Celgene Corporation | $26,684.23 | 2019-2025 | Zeposia |
| Mallinckrodt Hospital Products INC. | $26,030.08 | 2020-2025 | Acthar |
| Mylan Specialty L.P. | $23,732.12 | 2021-2024 | Glatiramer Acetate, Tobi Podhaler |
| Tg Therapeutics, INC. | $23,212.44 | 2021-2025 | |
| Avanir Pharmaceuticals, INC. | $22,491.47 | 2019-2022 | |
| Abbvie INC. | $19,279.63 | 2019-2025 | Ubrelvy, Qulipta, Botox |
| Teva Pharmaceuticals USA, INC. | $16,522.03 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Genentech USA, INC. | $13,500.85 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12,081.87 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $12,038.13 | 2020-2022 | |
| Allergan, INC. | $11,344.90 | 2019-2022 |
Show all 88 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $9,819.47 | 2020-2025 | Ponvory |
| Banner Life Sciences, LLC | $9,042.28 | 2022 | |
| Greenwich Biosciences, INC. | $6,410.58 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $6,351.98 | 2021-2025 | Purified Cortrophin Gel |
| Mylan Pharmaceuticals INC. | $4,358.16 | 2020 | |
| Mylan Institutional INC. | $2,231.27 | 2019 | |
| Ucb, INC. | $2,068.95 | 2019-2025 | Briviact, Rystiggo, Zilbrysq |
| Viatris Specialty LLC | $1,465.75 | 2025 | |
| Pfizer INC. | $1,188.28 | 2021-2025 | |
| Lundbeck LLC | $1,166.94 | 2019-2025 | Vyepti, Rexulti |
| Lilly USA, LLC | $1,055.03 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Neurocrine Biosciences, INC. | $1,034.46 | 2020-2025 | Ingrezza, Ongentys |
| Currax Pharmaceuticals LLC | $965.62 | 2020-2025 | Onzetra Xsail, Contrave |
| Beigene, LTD. | $887.50 | 2020 | |
| Alexion Pharmaceuticals, INC. | $839.49 | 2019-2025 | Soliris, Ultomiris |
| Supernus Pharmaceuticals, INC. | $775.68 | 2019-2025 | Qelbree, Oxtellar Xr |
| Biogen, INC. | $748.82 | 2021-2025 | Skyclarys, Leqembi |
| Mdd US Operations, LLC | $711.58 | 2020-2025 | Gocovri, Gocovri, Xadago |
| Axsome Therapeutics, INC. | $700.16 | 2023-2025 | Auvelity, Sunosi, Symbravo |
| Amgen INC. | $606.71 | 2020-2024 | Uplizna |
| Avadel Cns Pharmaceuticals, LLC | $564.34 | 2024-2025 | Lumryz |
| Argenx US, INC. | $501.88 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Harmony Biosciences LLC | $416.02 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $404.12 | 2020-2025 | Hyqvia, Gammagard |
| Hospira, INC. | $380.01 | 2023-2025 | |
| Csl Behring | $336.62 | 2019-2024 | Hizentra |
| Catalyst Pharmaceuticals, INC. | $327.49 | 2020-2024 | Firdapse, Fycompa |
| Upsher-Smith Laboratories LLC | $302.04 | 2019-2023 | |
| Sk Life Science, INC. | $298.90 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $288.66 | 2023-2025 | Nuedexta, Rexulti |
| Arbor Pharmaceuticals, INC. | $282.18 | 2019-2022 | |
| Eisai INC. | $254.89 | 2019-2024 | |
| Jazz Pharmaceuticals INC. | $250.78 | 2019-2022 | |
| Acorda Therapeutics, INC | $236.91 | 2019-2024 | Ampyra, Inbrija |
| Sunovion Pharmaceuticals INC. | $215.85 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $211.61 | 2019-2021 | |
| Abbott Laboratories | $207.01 | 2019-2025 | Proclaim, Infinity |
| Azurity Pharmaceuticals, INC. | $204.42 | 2023-2025 | Horizant, Horizant |
| Octapharma USA, INC. | $185.18 | 2024-2025 | Panzyga |
| Biohaven Pharmaceuticals, INC. | $175.60 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $164.15 | 2023-2025 | Quviviq, Quviviq |
| Acadia Pharmaceuticals INC | $154.13 | 2019-2025 | Nuplazid |
| Sumitomo Pharma America, INC. | $150.82 | 2023-2024 | Aptiom |
| Shire North American Group INC | $138.80 | 2019 | |
| Grifols USA, LLC | $137.32 | 2019-2025 | Xembify, Gamunex-C |
| Impel Pharmaceuticals INC. | $135.65 | 2023 | Trudhesa |
| Biohaven Pharmaceutical Holding Company LTD. | $132.62 | 2022 | |
| Avion Pharmaceuticals | $117.20 | 2022-2023 | Dhivy |
| Astrazeneca Pharmaceuticals LP | $114.89 | 2021-2025 | Flumist Quadrivalent, Evusheld, Wainua |
| Ipsen Biopharmaceuticals, INC | $112.41 | 2019-2022 | |
| Tonix Medicines, INC. | $104.93 | 2024-2025 | Zembrace Symtouch |
| Amneal Pharmaceuticals LLC | $102.55 | 2020-2024 | Rytary, Lioresal (Baclofen), Lyvispah |
| Bausch Health US, LLC | $92.19 | 2019 | |
| Kedrion Biopharma, INC. | $84.02 | 2023-2025 | Kedrab, Koate, Gammaked |
| Mylan INC. | $76.74 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $66.90 | 2024-2025 | Rexulti |
| Merz Pharmaceuticals, LLC | $63.16 | 2025 | Xeomin, Ampyra, Inbrija |
| Kyowa Kirin, INC. | $53.85 | 2020-2022 | |
| Cycle Pharmaceuticals INC | $53.23 | 2025 | Tascenso Odt, Bafiertam |
| Impel Pharmaceuticals LLC | $49.73 | 2024-2025 | Trudhesa |
| Tanabe Pharma America, INC. | $45.97 | 2022-2024 | |
| Adamas Pharmaceuticals, INC. | $43.43 | 2021 | |
| Neurelis, INC. | $42.78 | 2020-2022 | |
| Livanova USA, INC. | $42.36 | 2019-2020 | |
| Microtransponder, INC. | $37.15 | 2022-2025 | |
| Mallinckrodt Enterprises LLC | $32.05 | 2019 | |
| Vertical Pharmaceuticals, LLC | $30.02 | 2019 | |
| Philips North America LLC | $18.46 | 2019 | |
| Collegium Pharmaceutical, INC. | $17.89 | 2022 | |
| Promius Pharma LLC | $16.30 | 2019 | |
| Ge Healthcare | $15.53 | 2019 | |
| Almatica Pharma LLC | $13.38 | 2021 | |
| Boston Scientific Corporation | $12.85 | 2022 |
9 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$36,153.33 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Wynn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.